Xspray Pharma AB (publ) (0GHZ.L)

44.00 +0.10 (+0.23%) At close: 04:39PM BST

Xspray Pharma AB (publ)

Scheeles väg 2
Solna 171 65
Sweden
46 87 30 37 00
https://www.xspraypharma.com

Sector(s): 
Industry: 
Full-time employees: 26

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Per Andersson Ph.D.	Chief Executive Officer	3.74M	N/A	1967
Dr. Mustafa Demirbüker Ph.D.	Co-Founder and Science Director	N/A	N/A	N/A
Mr. Michael af Winklerfelt	Acting Chief Financial Officer	N/A	N/A	1972
Mr. Gérald Jesson	Vice President of Operations	N/A	N/A	N/A
Ms. Kerstin Hasselgren	Senior Advisor & Head of IR	N/A	N/A	1961
Ms. Linda Glimberg	Senior Vice President of Legal	N/A	N/A	1974
Ms. Charlotta Liljebris	Senior Vice President of Research & Development	N/A	N/A	1964
Mr. Edward P. Jordan M.B.A.	Chief Commercial Officer	N/A	N/A	1968
Ms. Anette Abrahamsson	Senior Vice President of Regulatory Affairs	N/A	N/A	1969
Christer Hallgren	Senior Vice President of Intellectual Property	N/A	N/A	1962

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company's product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.

Corporate governance

Xspray Pharma AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.